Novartis (NOVN.S) is happy with the performance of its consumer health joint venture with GlaxoSmithKline (GSK.L), in which the Swiss drugmaker has a minority stake, and is in no rush to exit the collaboration early, its chief executive said.
There has been speculation that Novartis might look to try and sell its 36.5 percent holding before an agreed trigger date of 2018, but Joe Jimenez played down the idea in a post-results call with analysts on Tuesday.
He noted the consumer business was doing well, with profit margins now improving, suggesting a bright outlook for the business.
There has been speculation that Novartis might look to try and sell its 36.5 percent holding before an agreed trigger date of 2018, but Joe Jimenez played down the idea in a post-results call with analysts on Tuesday.
He noted the consumer business was doing well, with profit margins now improving, suggesting a bright outlook for the business.
